Viking Therapeutics, Inc.

NasdaqCM:VKTX Stock Report

Market Cap: US$4.7b

Viking Therapeutics Management

Management criteria checks 2/4

Viking Therapeutics' CEO is Brian Lian, appointed in Sep 2012, has a tenure of 12.25 years. total yearly compensation is $12.63M, comprised of 4.9% salary and 95.1% bonuses, including company stock and options. directly owns 1.71% of the company’s shares, worth $80.86M. The average tenure of the management team and the board of directors is 5.3 years and 10.6 years respectively.

Key information

Brian Lian

Chief executive officer

US$12.6m

Total compensation

CEO salary percentage4.9%
CEO tenure12.3yrs
CEO ownership1.7%
Management average tenure5.3yrs
Board average tenure10.6yrs

Recent management updates

Recent updates

We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow

Dec 23
We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow

Viking Therapeutics: Holiday Gift

Dec 19

Viking Stock Pops, Then Drops On Latest Obesity/MASH Data: Why I'm Still Bullish

Dec 05

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Nov 04

Viking Therapeutics: Lots Of Positives

Oct 28

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics: Future Weight Loss Heavyweight?

Apr 02

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13
Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

CEO Compensation Analysis

How has Brian Lian's remuneration changed compared to Viking Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$99m

Jun 30 2024n/an/a

-US$97m

Mar 31 2024n/an/a

-US$94m

Dec 31 2023US$13mUS$615k

-US$86m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$72m

Dec 31 2022US$5mUS$612k

-US$69m

Sep 30 2022n/an/a

-US$62m

Jun 30 2022n/an/a

-US$59m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$4mUS$594k

-US$55m

Sep 30 2021n/an/a

-US$54m

Jun 30 2021n/an/a

-US$50m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$5mUS$577k

-US$39m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$4mUS$525k

-US$26m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$24m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$1mUS$485k

-US$22m

Sep 30 2018n/an/a

-US$21m

Jun 30 2018n/an/a

-US$20m

Mar 31 2018n/an/a

-US$19m

Dec 31 2017US$805kUS$440k

-US$21m

Compensation vs Market: Brian's total compensation ($USD12.63M) is above average for companies of similar size in the US market ($USD6.65M).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.

CEO

Brian Lian (58 yo)

12.3yrs

Tenure

US$12,628,061

Compensation

Dr. Brian Lian, Ph D., served as Director at Apricus Biosciences, Inc. He has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian has been an Inde...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Lian
President12.3yrsUS$12.63m1.71%
$ 80.9m
Gregory Zante
Chief Financial Officer5.3yrsUS$3.50m0.0010%
$ 48.6k
Marianne Mancini
Chief Operating Officer3.9yrsUS$3.51m0.18%
$ 8.7m
Michael Morneau
Vice President of Finance & Administration6.7yrsUS$619.56kno data
Geoffrey Barker
Senior Vice President of Pharmaceutical Development1.9yrsno datano data

5.3yrs

Average Tenure

58.5yo

Average Age

Experienced Management: VKTX's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Lian
President12.3yrsUS$12.63m1.71%
$ 80.9m
Scott Hecker
Scientific Advisorno datano datano data
Matthew Foehr
Independent Director10.6yrsUS$169.37k0.10%
$ 4.7m
J. Singleton
Independent Director10.6yrsUS$192.77k0.0085%
$ 402.6k
Charles Rowland
Independent Director7.4yrsUS$189.62k0.027%
$ 1.3m
Alan Cherrington
Scientific Advisorno datano datano data
G. Alexander Fleming
Scientific Advisorno datano datano data
Jay Magaziner
Scientific Advisorno datano datano data
David Bullough
Scientific Advisorno datano datano data
Lawson MacArtney
Independent Chairman10.6yrsUS$222.72k0.043%
$ 2.0m
Stephan Kemp
Scientific Advisorno datano datano data
S. Rouan
Independent Director5.4yrsUS$178.65k0%
$ 0

10.6yrs

Average Tenure

63.5yo

Average Age

Experienced Board: VKTX's board of directors are seasoned and experienced ( 10.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 08:22
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Viking Therapeutics, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG